Kevin Grogan is the Managing Editor Europe at Commercial. He specializes in a diverse range of topics, including medicine and healthcare, alternative medicine, and business economics, with a particular focus on medical technology and diagnostics. Kevin's insights and analyses have been featured in Informa and Citeline.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kevin Grogan's articles predominantly focus on the healthcare and pharmaceutical industries, specifically covering press releases, private sector announcements, industry-specific news, and government announcements. His coverage also includes scientific topics related to drug development and biotech sectors.
Given this focus, Kevin is likely to be interested in receiving pitches that provide insights into new drug developments, clinical trials advancements, or significant healthcare deals. He may particularly appreciate access to exclusive data or expert commentary from industry professionals with insider knowledge of recent developments within the pharmaceutical field.
It's clear that Kevin has a strong interest in both scientific breakthroughs and business-related news within the pharmaceutical and biotech sectors. Therefore, individuals or organizations aiming to reach out should consider offering unique angles on these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica.
Luc Truyen tells Scrip about indication expansions for the firm's mega-blockbuster and broadening the pipeline beyond FcRn inhibition.
The UK biotech's chief scientific officer, Simon Westbrook, told Scrip at EULAR that LEVI-04's ability to target symptoms and potentially modify the disease could unlock a mega-blockbuster for osteoarthritis.
The first FcRn inhibitor to enter clinical trials in systemic lupus erythematosus has met its primary endpoint, handing Johnson & Johnson a proof-of-concept win in one of the most difficult-to-treat autoimmune diseases.
Eli Lilly's plan to position itself as a leading player in the pain space, with a particular focus on non-opioid treatments, is continuing apace with its acquisition of 4E Therapeutics.
These are transformational times for Spanish epigenetics pioneer Oryzon Genomics as it moves towards a potentially registrational study for its lead asset, iadademstat, in acute myeloid leukemia (AML).
The company has held a successful end-of-Phase II meeting with the US FDA to advance zelicapavir into late-stage trials.
The rumor mill has proved correct and AbbVie has announced a near $11bn acquisition of Apogee Therapeutics, a deal that appears to make a lot of
The oral BTK inhibitor has just got the nod in the EU for non-relapsing secondary progressive multiple sclerosis after a rejection from the US FDA at the end of 2026.
